Cart
sales@molnova.com
CK7
CAS No. 507487-89-0
CK7( [4-(2-Amino-4-methyl-thiazol-5-YL)-pyrimidin-2-YL]-(3-nitro-phenyl)-amine )
Catalog No. M28803 CAS No. 507487-89-0
CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 128 | In Stock |
|
| 5MG | 117 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 376 | In Stock |
|
| 50MG | 576 | In Stock |
|
| 100MG | 886 | In Stock |
|
| 200MG | 1190 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCK7
-
NoteResearch use only, not for human use.
-
Brief DescriptionCK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
-
DescriptionCK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
-
In Vitro——
-
In Vivo——
-
Synonyms[4-(2-Amino-4-methyl-thiazol-5-YL)-pyrimidin-2-YL]-(3-nitro-phenyl)-amine
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorΔ5D
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number507487-89-0
-
Formula Weight655.69
-
Molecular FormulaC28H23N12O4S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (38.07 mM)
-
SMILESCc1c(-c2nc(Nc3cc([N+]([O-])=O)ccc3)ncc2)sc(N)n1Cc1c(-c2nc(Nc3cc([N+]([O-])=O)ccc3)ncc2)sc(N)n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time Ikuo Miyahisa, Hideo Suzuki, Atsushi Mizukami, Yukiya Tanaka, Midori Ono, Mark S. Hixon, and Junji Matsui Publication Date (Web): August 10, 2016 (Letter)
molnova catalog
related products
-
THZ1 2HCl
THZ1 2HCl is a selective, covalent, and allosteric inhibitor of CDK7 with an IC50 of 3.2 nM. THZ1 2HCl has antiproliferative effects on a variety of cancer cell lines.
-
Senexin-A
A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
-
23-epi-26-Deoxyactei...
23-epi-26-Deoxyactein has anti-inflammatory activity, it inhibits nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. It also has anti-cancer activity, it can inhibit growth of the MCF7 human breast cancer cells and induce cell cycle arrest at G1.
